DocWire News Editors

DocwireNews

A study being presented at the CHEST Annual Meeting 2019 found that mepolizumab reduced exacerbations in patients with severe eosinophilic asthma, regardless of baseline oral corticosteroid (OCS) use.The previously reported SIRIUS clinical trial demonstrated that mepolizumab had a significant glucocorticoid-sparing effect and reduced exacerbations in patients with severe eosinophilic asthma receiving maintenance OCS.In this post-hoc subgroup meta-analysis of patients in the MENSA and MUSCA studies, researchers assessed the annual rate of clinically significant exacerbations (defined as requiring administration of systemic glucocorticoids for three or more days or an emergency department [ED] visit and hospitalization) in patients receiving mepolizumab 100 mg subcutaneously or placebo. Exacerbations were assessed at week 32 in the MENSA study and week 24 in the MUSCA study.A total of 936 patients were included: 227 (24%) had used maintenance OCS and 709 (76%) had not. Among patients receiving maintenance OCS, the median dose was 10 mg daily. Maintenance OCS was associated with a greater disease burden, higher mean St. George&rsquo;s Respiratory Questionnaire total score (using OCS, 52.9; not using OCS, 45.2), higher mean Asthma Control Questionnaire-5 score (using OCS, 2.44; not using OCS, 2.16), and greater number of exacerbations requiring hospitalization or an ED visit (using OCS, n=87/227 [38%]; not using OCS, n=221/709 [31%]).All patients achieved a clinically meaningful reduction in exacerbation rate with mepolizumab compared with placebo. A numerically higher exacerbation reduction was observed in patients not receiving maintenance OCS (rate ratio for mepolizumab/placebo: using OCS, 0.66 [95% CI, 0.47 to 0.93] vs. not using OCS, 0.37 [95% CI, 0.28 to 0.48]).ReferenceSmith S, Lugogo N, Pavord I, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma irrespective of baseline maintenance OCS use: meta-analysis from two Ph3 trials. Presented at the CHEST Annual Meeting 2019. October 19-23, 2019; New Orleans, Louisiana.&nbsp;

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Mepolizumab Reduces Exacerbations in Patients With Asthma

CHEST 2019 Conference Coverage

A study being presented at the CHEST Annual Meeting 2019 found that mepolizumab reduced exacerbations in patients with severe eosinophilic asthma, regardless of baseline oral ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe